Trials / Completed
CompletedNCT00329004
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
A Phase I Dose Escalation Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine the highest dose of the drug (BMS-690514) that can be safely given to patients with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-690514 | Tablets, Oral, up to 300 mg, once daily, up to 24 mos |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2006-05-24
- Last updated
- 2011-01-25
Locations
7 sites across 4 countries: United States, Canada, France, Spain
Source: ClinicalTrials.gov record NCT00329004. Inclusion in this directory is not an endorsement.